Molecule | Jotup

Eleven Therapeutics Welcomes Dr. Paloma H Giangrande as Chief Technology Officer

Retrieved on:

木曜日, 1月 11, 2024

Entrepreneurship, DSM-IV codes, Specialization, Therapy, Research, Biotechnology, RNA, University, Nucleic acid, TEL, Molecule, Messenger, Medical device

CAMBRIDGE, Mass, CAMBRIDGE, England and TEL AVIV, Israel, Jan. 11, 2024 /PRNewswire/ -- Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr. Paloma H Giangrande as the company's Chief Technology Officer (CTO).

Key Points:

CAMBRIDGE, Mass, CAMBRIDGE, England and TEL AVIV, Israel, Jan. 11, 2024 /PRNewswire/ -- Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr. Paloma H Giangrande as the company's Chief Technology Officer (CTO).
Bringing a wealth of experience, Dr. Giangrande has been a prominent figure in nucleic acid therapeutics for over a decade.
Prof. Yaniv Erlich, CEO and Co-Founder of Eleven Therapeutics, expressed his enthusiasm about Dr. Giangrande joining the team, stating, "We are thrilled to welcome Dr. Paloma Giangrande to Eleven Therapeutics.
Dr. Giangrande will officially assume her role as Chief Technology Officer at Eleven Therapeutics on January 2nd, 2024.

NeuroX1 Inc. and Everlum Bio Inc. have established a co-development partnership focused on accelerating the pre-clinical development of small molecule therapeutics

Retrieved on:

木曜日, 1月 4, 2024

Molecule, DSM-IV codes, Partnership, Research, AI, Therapy, Neurology, Inc., Pharmaceutical industry

AUSTIN, Texas, Jan. 4, 2024 /PRNewswire-PRWeb/ -- NeuroX1 Inc. and Everlum Bio Inc. have established a co-development partnership focused on accelerating the pre-clinical development of small molecule therapeutics. This collaboration aims to address a broad spectrum of neurological disorders, encompassing both widespread and rare conditions. The partnership leverages NeuroX1 Inc.'s expertise in AI-powered drug discovery and neurotherapeutics in conjunction with Everlum Bio Inc.'s specialization in personalized medicine. This strategic alliance underscores the commitment of both companies to pioneering research and represents a significant milestone in the advancement of the biotech industry in Central Texas.

Key Points:

AUSTIN, Texas, Jan. 4, 2024 /PRNewswire-PRWeb/ -- NeuroX1 Inc. and Everlum Bio Inc. have established a co-development partnership focused on accelerating the pre-clinical development of small molecule therapeutics.
The partnership leverages NeuroX1 Inc.'s expertise in AI-powered drug discovery and neurotherapeutics in conjunction with Everlum Bio Inc.'s specialization in personalized medicine.
Joining forces with Everlum Bio Inc. represents a pivotal step in our mission to revolutionize neurological drug discovery.
Rick Barkley, CEO of Everlum Bio Inc., added, "This partnership with NeuroX1 Inc. is a testament to our commitment to advancing neurological therapeutics, particularly in the area of rare pediatric neurological diseases.

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Retrieved on:

木曜日, 12月 14, 2023

Molecule, Conference, Therapy, DARPin, Molecular Partners

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA.

Key Points:

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA.
In addition, members of Molecular Partners’ leadership team will participate in upcoming investor events in Switzerland during January 2024.

Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Sustainable Crop Protection Solutions

Retrieved on:

木曜日, 12月 14, 2023

Seed, Drug design, Agriculture, Software, Deep learning, Pharmacy, Farmer, Software as a service, Molecule, Health, Crop protection, Artificial intelligence, Climate change, Food, Food security, Safety, Environment, Pharmaceutical industry

Makya™ is based on deep learning generative models which design and optimize, in-silico, novel molecules that satisfy multiple parameters, such as efficacy, selectivity, safety, and sustainability.

Key Points:

Makya™ is based on deep learning generative models which design and optimize, in-silico, novel molecules that satisfy multiple parameters, such as efficacy, selectivity, safety, and sustainability.
The technology brings new insights and directions into the molecular discovery process based on a comprehensive data-driven chemical structure generation technology.
“Bayer’s CropKey approach to crop protection innovation is made possible by data-driven breakthrough technologies such as those made accessible by Iktos.
This way, the promise of AI to dramatically improve discovery will have a better chance to be realized and impact small molecule active ingredient development.”

Anima Biotech to Present at the 6th Annual RNA-Targeted Drug Discovery & Development Summit

Retrieved on:

月曜日, 12月 11, 2023

Molecule, RNA, Drug discovery, Messenger, Gal, AI, Business development, Annual, Tech, Discovery, Development, Drug design, Pharmaceutical industry

BERNARDSVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Anima Biotech, the leading Tech.Bio in the discovery of mRNA drugs and targets, today announced their participation in the upcoming 6th Annual RNA-Targeted Drug Discovery and Development Summit taking place in Boston, MA from December 12 – 14, 2023.

Key Points:

BERNARDSVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Anima Biotech, the leading Tech.Bio in the discovery of mRNA drugs and targets, today announced their participation in the upcoming 6th Annual RNA-Targeted Drug Discovery and Development Summit taking place in Boston, MA from December 12 – 14, 2023.
During the conference, Anima Biotech’s Vice President of Business Development, Gal Gur, Ph.D., will participate in a panel discussion titled, “Overcoming Key Challenges to Improve Drug Design & Discovery for Novel Approaches,” taking place on Wednesday, December 13th at 3:30 PM EST.
The panel will foster a discussion centered around navigating the landscape of RNA-targeting small molecules and how companies are leveraging this approach to develop novel therapeutic solutions.
The Annual RNA-Targeted Drug Discovery & Development Summit brings together scientific researchers and biotechnology professionals to discuss new approaches to RNA drug discovery and scientific breakthroughs across the industry.

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

Retrieved on:

月曜日, 12月 4, 2023

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that promising new data on the effect of ATH434 in a Parkinson’s disease primate model was presented at the Future of Parkinson’s Disease Conference 2023 that took place November 30 – December 3, 2023 in Austin, TX, USA.

Key Points:

The presentation demonstrated that ATH434 treatment improved motor performance and general function in monkeys with experimentally induced Parkinson’s disease.
The favorable impact on Parkinson’s symptoms was associated with lower iron levels in the area of pathology.
In addition, ATH434 treatment increased levels of synaptophysin, a protein marker that reflects functional connections between neurons.
In addition, monkeys with improved scores had higher right dorsal striatal synaptophysin, indicating functional recovery of nerve endings in this critical motor pathway.

Noor Riyadh 2023: The world’s largest annual festival of light and art returns to Saudi Arabia’s Capital, with over 120 artworks by more than 100 local and international artists

Retrieved on:

木曜日, 11月 30, 2023

Molecule, Cosmos, Moon, Guinness, Tuwaiq, School, Random International, White people, Desert, KAFD, Kingdom Centre, Identity, TVC, Connectivity, Metal, Exhibition, Light, Argote, Social, Growth, Memory, Sans, Metaphor, House, Life, Interior design

RIYADH, Saudi Arabia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Noor Riyadh, the world's largest light art festival, will return to Saudi Arabia's capital for its third edition from November 30 to December 16, 2023. More than 120 artworks, large-scale installations and immersive projections will light up the city, bringing art to the people and boosting the creative economy. The event supports the Riyadh Art objective of transforming Riyadh into an awe-inspiring 'gallery without walls', engaging diverse audiences, transcending boundaries, and integrating art into the urban fabric.

Key Points:

Photos © Noor Riyadh 2023, a Riyadh Art Program
RIYADH, Saudi Arabia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Noor Riyadh, the world's largest light art festival, will return to Saudi Arabia's capital for its third edition from November 30 to December 16, 2023.
More than 120 artworks, large-scale installations and immersive projections will light up the city, bringing art to the people and boosting the creative economy.
The event supports the Riyadh Art objective of transforming Riyadh into an awe-inspiring 'gallery without walls', engaging diverse audiences, transcending boundaries, and integrating art into the urban fabric.
Among the highlights at Noor Riyadh is a number of site-specific commissions by 35 established and emerging Saudi artists.

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Retrieved on:

火曜日, 11月 28, 2023

Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.

Key Points:

Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.
ET [Platform D | Epilepsy Therapies]
Summary: Combined preclinical and clinical data demonstrate PRAX-628 is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy.
Summary: This study provides novel insights into the clinical validity of commonly used preclinical seizure models across the clinical epilepsy spectrum.
Oral presentation highlighting clinical updates from our PRAX-562 small molecule platform at the annual clinician, researcher, and family gathering for SCN8A

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

Retrieved on:

水曜日, 11月 15, 2023

Molecule, Alzheimer's disease, Cell, Autophagy, Research, Parkinson's disease, Therapy, Disease, Metabolism, Cognition, Genomics, Sympathetic nervous system, Deficit spending, Lewy body, Society, Pharmaceutical industry, Residential care, Generic drug, Dementia

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases.

Key Points:

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases.
The effect of two chemically distinct σ-2 receptor modulators in a mouse model of Alzheimer’s disease on gene and protein expression are presented.
Fox Foundation grant award is presented defining the impact of σ-2 receptor modulators on gene and protein expression.
In two different rat models of Parkinson’s disease, the same two σ-2 receptor modulators are shown to effect pathways associated with Parkinson's disease, including cell survival, metabolism, autophagy, and protein/lipid transport.

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

Retrieved on:

水曜日, 11月 15, 2023

Molecule, ISCB Senior Scientist Award, Annual general meeting, HGF, Cell proliferation, Athira Pharma, Neuron, Microglia, LPS, Oxidative stress, Neurogenesis, Neuroinflammation, Society, Pharmaceutical industry, Medical imaging, Neuroscience, Neurotrophic factors

“We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.

Key Points:

“We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.
“Our latest data demonstrate consistent neuroprotective effects of fosgonimeton and provide insights into the mechanisms by which it preserves neurons from degeneration and reduces neuroinflammation.
Wei Wu, Ph.D., Senior Scientist II, Athira Pharma, presented preclinical research demonstrating the cellular mechanisms by which fosgonimeton induces anti-inflammatory effects in BV2 microglia cells.
The anti-inflammatory effects of fosgonimeton demonstrated in these models suggest it may have the potential to help reduce neuroinflammation, a key pathological feature of several neurodegenerative diseases.